Trials show new drug can ease symptoms of chronic cough

February 25, 2020

Two trials of a new drug have shown that at low doses, it can ease the often distressing symptoms of chronic cough with minimal side effects.

Principle researcher Jacky Smith, a Professor of Respiratory Medicine at The University of Manchester and a consultant at Wythenshawe Hospital, says Gefapixant has the potential to have a significant impact on the lives of thousands of suffers.

Higher doses can reduce the sense of taste, though at 50mg, the effect is much reduced, say the research team.

The drug is being developed in collaboration with the pharmaceutical company MSD, who have funded the trials.

The study published in Lancet Respiratory Medicine today shows that in a 12-week trial of 253 patients- the largest of its kind- 80% of patients had a clinically significant response to a dose of 50mg.

A dose of 7.5mg reduced the coughing by 52%, 20mg by 52% and 50mg by 67% from baseline. Around a quarter did not respond to the drug.

And another 16-day study describing a 57 patient trial, also published in the European Respiratory Journal this week, showed that as little as 30mg of the drug could be effective - much lower than previously thought.

Both studies were randomised and double blind, in which neither the participants nor the experimenters knew who received the treatment.

The drug is now in two larger global phase 3 trials, carried out to confirm and expand on the safety and effectiveness results from the previous research.

Chronic coughing is thought to affect between 4 and 10% of the population, some of whom cough thousands a time a day over many years.

While many patients improve with treatment of associated conditions such as asthma, gastroesophageal reflux disease and nasal disease, many do not.

The condition can cause abdominal pain, urinary incontinence in women, as well as anxiety, depression and difficulty sleeping.

Professor Smith said: "This drug has exciting prospects for patients who suffer from the often distressing condition of chronic cough.

"Effective treatments for cough are a significant unmet clinical need and no new therapies approved in over 50 years.

"Billions of pounds are spent annually on over-the-counter cough and cold medicines despite a lack of evidence to support their efficacy, concerns about the potential for abuse and risk of harm in overdose."

Gefapixant is able to target P2X3receptors in the nerves which control coughing and the team monitored the impact of the drug using a special cough monitoring device they developed which counts coughs.

The drug was initially developed as a pain killer, until the researchers discovered it had a significant impact on chronic cough.

Some unlicensed drugs have also been shown to improve chronic cough, but their use is limited by unpleasant side effects.

It is thought a chemical called adenosine triphosphate (ATP), released as a response to inflammation in airways, may be an important mechanism for patients with chronic cough.

Professor Smith added: "We can't yet say when or if this drug will be available on prescription, however, if the phase 3 trial is successful then it would certainly be a major step towards everyday use.

"Though it's fair to say the drug is not a cure for chronic cough, it can and often does reduce the frequency of coughing substantially"

"That could make a big difference to patients who often struggle with this condition which can make such a big impact on their lives."

Retired journalist Nick Peake, from Warrington, who was a television director at ITV and the BBC, has been suffering from chronic cough for 25 years.

He said: "Coughing has blighted my life : every day without fail I cough for the first two hours, soon after I wake up often every 30 seconds. It wears me out.

"It comes and goes through the day: usually after a meal, or when I have a change of atmosphere - out of warm into cold, or if I exercise too hard.

"It often stops me getting to sleep at night, but then I might wake up at 3 or 4 in the morning and start coughing.

He added: "The coughing interferes with conversations, sometimes it stop me singing which I love to do. It's embarrassing when I'm with people - I find myself apologising a lot, and I have no control over it.

"So I'm often in despair about it and it can make me miserable. How my wife has put up with it all this time I don't know.

"It's been going on for so long and I'm thoroughly fed up with it, and desperate for a cure to be found."
-end-
Notes for editors

Types of subjects: human

Type of evidence: randomised double blind trials

Type of papers: peer reviewed

Professor Jacky Smith and Nick Peake are available for interview

She is Professor of Respiratory Medicine at The University of Manchester and Honorary Consultant at Wythenshawe Hospital, and Director of NIHR Manchester Clinical Research Facility (CRF)

The papers Gefapixant in two randomized dose-escalation studies in chronic cough and Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough in a phase 2b randomised controlled trial are available

Nick Peake's blog Cough Up can be found at http://coughup.blogspot.com

For media enquiries contact:

Mike Addelman

Media Relations Officer

Faculty of Biology, Medicine and Health

University of Manchester

07717 881567

University of Manchester

Related Chronic Cough Articles from Brightsurf:

Tracking flight trajectory of evaporating cough droplets
The ongoing COVID-19 pandemic has led many to study airborne droplet transmission in different conditions and environments, and in Physics of Fluids, researchers from A*STAR conducted a numerical study on droplet dispersion using high fidelity air flow simulation.

COVID-19 cough clouds in closed spaces
As the pandemic continues, researchers have increasingly focused on how respiratory droplets carrying the coronavirus travel and contaminate the air after an infected person coughs.

The good cough and the bad cough
Researchers might be able to treat a troublesome cough in disease without disrupting the protective cough we need for optimal lung health, by targeting the different brain circuits involved.

Study: Cough that spreads tuberculosis has pain-linked trigger
University of Texas System researchers have pinpointed a molecule that the tuberculosis bacterium manufactures to induce the coughing that spreads the disease by triggering a pain-receptor response.

Study: Tuberculosis bacteria trigger cough, facilitating spread
The bacteria that cause the deadly lung disease tuberculosis appear to facilitate their own spread by producing a molecule that triggers cough.

Trials show new drug can ease symptoms of chronic cough
Two trials of a new drug have shown that at low doses, it can ease the often distressing symptoms of chronic cough with minimal side effects.

The Lancet Respiratory Medicine: New therapy could help relieve persistent cough
A new treatment - called gefapixant - may reduce the frequency of coughing, including in patients who have suffered from a chronic cough for more than 15 years, according to results from a phase 2b clinical trial which lasted 12 weeks and included 253 people, published in The Lancet Respiratory Medicine journal.

Shortness of breath and cough increase as first symptom of lung cancer
GPs are being urged to consider shortness of breath and cough as potential predictors of lung cancer, after a study found they were becoming more common as the first symptom in diagnosis.

Whooping cough evolving into a superbug
Whooping cough bacteria are becoming smarter at colonising and feeding off unwitting hosts -- whether they have been vaccinated or not -- strengthening calls for a new vaccine, according to UNSW researchers.

Doctors more likely to recommend antihistamines rather than cough & cold medicine for kids
For respiratory infections in children under 12, physicians are increasingly more likely to recommend antihistamines and less likely to recommend cough and cold medicines, a Rutgers study found.

Read More: Chronic Cough News and Chronic Cough Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.